Dataset opportunity
Quantadt — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Quantadt, usable for Diagnostic AI and Computer Vision.
Score
67.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market was valued at $1.88 billion in 2025, projected to grow at a CAGR of 36.91% (2026-2034).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
Raised $245M to expand commercial operations and digital offerings
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Quantadt provides a high-value Medical Imaging Dataset that integrates image modalities with telemetry from medical devices (`industrial_data`, `iot_data`) and longitudinal patient outcomes from `medical_records`. This multi-modal assembly is specifically structured to accelerate the development and validation of Diagnostic AI algorithms, offering a comprehensive view of the patient journey.
The global AI in Medical Imaging market was valued at $1.88 billion in 2025 and is projected to exhibit a CAGR of 36.91% through 2034. [4] While access is complex, requiring navigation of HIPAA/GDPR regulations and hospital data agreements, the inherent rarity and richness of this dataset make it a crucial asset for buyers aiming to capture value in the rapidly growing healthcare AI sector. ⚠ Diligence (valuable data, access to negotiate): Data involves highly sensitive clinical health records (HIPAA/GDPR).; Ownership is likely shared between Quanta (telemetry) and healthcare providers (patient outcomes).; Access requires navigating medical device data regulations and hospital-specific data sharing agreements. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Quantadt owns a rare, proprietary dataset combining medical images with rich, corresponding time-series data from its dialysis systems. This integrated data is a powerful asset for training sophisticated diagnostic AI models that link device performance directly to patient outcomes. For medical-AI firms, acquiring this data offers a significant competitive edge to develop next-generation predictive analytics in a global market projected to grow at nearly 37% annually.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the market's rapid expansion for **Diagnostic AI** solutions, as evidenced by a projected **CAGR of 36.91%**. [4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — The company's core business is manufacturing and selling portable dialysis machines; the proprietary data generated by these connected devices is a by-product, making it an ideal target. Issues: The initial sourcing information was incorrect; the company does not sell medical imaging datasets but manufactures and sells dialysis equipment and services.
- Deep Qualification90
⚠ needs review — Quantadt is a medical device manufacturer specializing in hemodialysis systems, not a data broker. The opportunity hypothesis is based on a fundamentally incorrect data label ('Medical Imaging Dataset'), as the company's products generate dialysis telemetry data, not images. [dataset_type implausible vs real activity: The company's actual business is manufacturing and selling hemodialysis systems (Quanta Dialysis System), not medical imaging. The data generated is telemetry and patient vitals from dialysis treatment, not images. [2, 6, 13]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>Modernize evidence generation with unified strategies and AI to accelerate time to market.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/HDXCMuwpTo4W3TZPDuJxBKWjDpFEhQnan8PL_oR0GcQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9JbGx1bWluYS1idWlsZGluZy1lbnRyYW5jZS5qcGc=.webp" /></div></figure><p>The gene sequencing company this week named a new chief commercial officer and chief legal officer.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/1DFG8o5dN41yUuNj7aAn5NjK5NwP8GcncqA_DY_49uE/g:nowe:0:201/c:2121:1198/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE1MjY5MzAyLmpwZw==.webp" /></div></figure><p>The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.</p>”
IoT / sensor data
This evidence points to granular time-series data from device sensors, crucial for AI companies developing models to optimize treatment efficacy and predict device performance.
Medical records / imaging
This confirms the existence of proprietary medical images managed within a cloud platform that tracks the patient journey from hospital to home, offering a unique longitudinal view for training diagnostic AI.
Industrial data
This indicates ownership of operational data on system efficiency and maintenance, valuable for creating predictive maintenance algorithms and optimizing the device's lifecycle.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Quantadt Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.88 billion in 2025, projected to grow at a CAGR of 36.91% (2026-2034) (source: Fortune Business Insights). [4]. Investment score 67.9/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Robsurgical — Medical Imaging Dataset Opportunity
View opportunity →healthcareIntelligent Implants — Medical Imaging Dataset Opportunity
View opportunity →healthcareYourway — Sensor Telemetry Dataset Opportunity
View opportunity →